Rovi stock trades 32.76 percent below its 52-week high

Published on 10/09/2026 at 14:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi will report nine-month results on November 5, 2026. Rovi stock costs EUR 58.30 on October 9, 2026 versus a EUR 74.36 average target.

Key points in brief

Rovi stock was EUR 58.30 at Lang & Schwarz on October 9, 2026, 32.76 percent below its 52-week high of EUR 86.70.
Rovi will publish its first nine months 2026 results on November 5, 2026.
First-half 2026 revenue rose 13.20 percent to EUR 357.00 million, while net profit reached EUR 84.40 million.
The average analyst target was EUR 74.36, 27.55 percent above the Lang & Schwarz price.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) was trading at EUR 58.30 at Lang & Schwarz on October 9, 2026 at 2:12 p.m. CEST, 32.76 percent below its 52-week high of EUR 86.70. The company will publish its first nine months 2026 results on November 5, 2026, according to Rovi.

Nine-month results are next

The November 5 release is the next scheduled financial milestone for Laboratorios Farmaceuticos ROVI, S.A. The report will show whether the growth mix seen in the first half of 2026 is continuing into the second half.

The chronology is clear. On May 6, 2026, Rovi reported first-quarter revenue of EUR 154.70 million; on July 23, 2026, first-half revenue reached EUR 357.00 million, up 13.20 percent; on October 9, 2026, the Lang & Schwarz quote stood at EUR 58.30.

What does the earnings mix mean?

According to Rovi, first-half revenue grew 13.20 percent and gross margin expanded by 6.50 percentage points. Finanzas.com reported that net profit reached EUR 84.40 million, up 113.00 percent, while adjusted EBITDA excluding the EUR 62.40 million Phoenix bargain-purchase gain fell 10.00 percent to EUR 58.80 million.

The operating picture is mixed in a useful way. CDMO sales rose 38.00 percent to EUR 106.30 million, and Okedi sales increased 27.00 percent to EUR 34.00 million, while heparin sales declined 4.00 percent to EUR 130.10 million, according to Finanzas.com. The next report therefore matters most for recurring profitability, not merely reported net income.

Analyst target remains higher

Finanzas.com cited nine analysts with an average target of EUR 74.36 and a range from EUR 64.20 to EUR 83.00. The average target lies 27.55 percent above the Lang & Schwarz price, giving the November report a clear test: growth must become more recurring while Phoenix capacity is integrated.

Two forward dates frame the calendar: the nine-month 2026 results are scheduled for November 5, 2026, according to Investing.com, and full-year 2026 results are listed for February 24, 2027, by Barrons.

Stock remains below yearly high

Rovi was trading at EUR 58.30 at Lang & Schwarz on October 9, 2026 at 2:12 p.m. CEST, down 0.34 percent versus the Lang & Schwarz prior close of EUR 58.50. The company trades on BME, where its primary listing is identified as ROVI.MC under ISIN ES0157261019.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.